Ye Weiguo sold $69K of GYRE
Ye Weiguo (Chief Operating Officer) sold 11,000 shares of GYRE THERAPEUTICS, INC. (GYRE) at an average of $6.25 ($6.15–$6.35) across 3 trades over 2026-06-09 to 2026-06-18.
How this was made
The 30-second read
Why it matters
The disclosed open-market sale by the COO is a sentiment datapoint; without accompanying company-specific news, it is unlikely to drive a durable repricing.
Market read
Traders may monitor insider activity as a sentiment input, but this filing alone does not introduce new fundamentals.
What to watch
The article notes no 10b5-1 plan, but it does not provide the insider’s rationale, tax context, or whether other planned sales exist.
Background
The article is an SEC Form 4 insider transaction disclosure for GYRE Therapeutics, Inc.
Ticker impact
SEC Form 4 shows COO Ye Weiguo sold 11,000 shares of GYRE in open-market trades at $6.15–$6.35 (filed June 22).
Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.
The filing is primary-source and company-specific, but it provides only an insider transaction size/price range without new operational, clinical, or financial information.
Market effects
Minimal; insider-sale filings typically do not change sector fundamentals.
None indicated.
None indicated.
Counterpoint
Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs rather than bearish expectations.
Key entities
- issuerGYRE Therapeutics, Inc.
Subject of the Form 4 insider transaction; COO sold shares in June 2026.
- insiderYe Weiguo
Chief Operating Officer who executed open-market sales totaling $68,700.